News platforms as important as content, study claims

Share this article:

Health marketing communications firm Enspektos did a deep dive into desktop and media habits and found that who you are in the healthcare industry determines  how much you trust the information that pops up on the screen.

The overall trend was that doctors, nurses and pharmacists overwhelmingly trust information from health websites accessed from desktops more than information obtained via mobile and social network platforms, and they consider news from the Twitterverse to be the least credible. The study found that 78% of polled doctors trusted websites, compared with 69% of nurses and 71% of pharmacists, yet for all three professions, 85% of the polled individuals said they frequently tap the web for medical information.

Mobile content had credibility among 70% of the polled doctors, 46% of the nurses and 61% of the pharmacists, while health information on social networks was considered credible among 10% of the polled docs,  9% of the nurses and 6% of the pharmacists.

The relatively low fondness for social media, however, does not mean that pharma should continue to stay away from the communal space—the report found that these same healthcare providers changed their minds about the integrity of the social-media news flow if they dipped into the social space while doing work-related web surfing or just after scanning websites for related health information.
Share this article:

Email Newsletters

More in News

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...

Pfizer Q2 sales slip, but still beat expectations

Pfizer Q2 sales slip, but still beat expectations

Patent losses and lost co-promotion agreements put a dent in sales.

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?